Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korean CHA Bio, U.S. ACT Ink $1.9 Billion Licensing Deal

This article was originally published in PharmAsia News

Executive Summary

South Korean biotech CHA Bio & Diostech has licensed a retinal pigment epithelium technology from U.S.-based Advanced Cell Technology. The agreement restricts CHA Bio's development and marketing of an end product to treat eye diseases to Korea only. The contract calls for milestone payments to ACT for as much as $1.9 billion, with ACT to have U.S. development rights. ACT expects to begin clinical trials later this year. The two companies have been engaged in other joint ventures for hemangioblast technology. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts